ALC Alcon Inc.

Alcon Announces Results of 2024 Annual General Meeting

Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM).

A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,068,314.80, were represented at today's AGM.

Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who all stood for re-election, namely Lynn Bleil, Raquel Bono, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel and Dieter Spälti, for a term of one year.

In addition, shareholders re-elected Thomas Glanzmann, Karen May, Scott Maw and Ines Pöschel to form the Compensation Committee for a period of one year.

Discharge was granted to the members of the Board of Directors and the members of the Executive Committee for the 2023 financial year.

In two separate binding votes, shareholders approved the maximum aggregate amount of compensation of the Board of Directors for the next term of office ending at the 2025 Annual General Meeting, and the Executive Committee for 2025 financial year.

Shareholders also accepted the 2023 Non-Financial Matters Report in a non-binding, consultative vote.

Additionally, the 2023 Compensation Report was not accepted in a consultative, non-binding vote.

Alcon shareholders approved the operating and financial review of Alcon Inc., the annual financial statements of Alcon Inc. and the consolidated financial statements for 2023.

Shareholders also approved that a gross dividend of CHF 0.24 per dividend-bearing share be declared, and that, after appropriation of the proposed dividend, the remaining amount of available earnings be carried forward.

Pricewaterhouse Coopers SA, Geneva, was re-elected as statutory auditors for the 2024 financial year. Hartmann Dreyer Attorneys-at-Law was also re-elected as the independent representative for a term of one year extending until the 2025 AGM.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at .

Connect with us on



EN
08/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Alcon Inc.

 PRESS RELEASE

Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales...

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three months ended March 31, 2024. For the first quarter of 2024, sales were $2.4 billion, an increase of 5% on a reported basis and 7% on a constant currency basis1, as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.50 and core diluted earnings per share2 of $0.78 in the first quarter of 2024. "Our first-quarter results reflect the outstanding work done by our more than 25,000 associates across both our Surgical and Vision ...

 PRESS RELEASE

Alcon Announces Results of 2024 Annual General Meeting

GENEVA--(BUSINESS WIRE)-- Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of all proposed binding resolutions at its 2024 Annual General Meeting (AGM). A total of 326,707,870 shares with a nominal value of CHF 0.04 each, representing an aggregate nominal value of CHF 13,068,314.80, were represented at today's AGM. Shareholders re-elected F. Michael Ball as member and Chair of the Board of Directors, and the other members of the Board who all stood for re-election, namely Lynn Bleil, Raquel Bono, Arthur Cumm...

 PRESS RELEASE

Alcon Publishes Agenda for 2024 Annual General Meeting

GENEVA--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care, will hold its Annual General Meeting (AGM) on May 8, 2024. Alcon is pleased to welcome shareholders to its second in-person AGM since becoming an independent, standalone company. The company looks forward to hearing directly from its shareholders at this open format meeting. The agenda for this 2024 AGM consists of the regular items, as well as, newly, the vote on the 2023 Report on Non-Financial Matters. The invitation to the AGM, including explanatory information on individual agenda items, will be publishe...

 PRESS RELEASE

Alcon Strengthens Leadership in IOL Innovation with the launch of the ...

BENGALURU, India--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the launch of the Clareon® Family of intraocular lenses (IOLs) in India. Utilizing Alcon’s most advanced IOL material in its 20+ years of IOL innovation, Clareon delivers consistent visual outcomes and exceptional clarity that lasts.°,12-18 Clareon’s clarity is born out of a glistening-free§ IOL material that has among the lowest levels of haze and subsurface nanoglistenings (SSNGs), compared to leading competitor IOLs.†,*,12-14 The Clareon pla...

 PRESS RELEASE

Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone

TORONTO--(BUSINESS WIRE)-- Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today proudly announces AcrySof® IQ Vivity® and Clareon® Vivity extended depth of focus (EDOF) intraocular lens (IOL) has surpassed more than one million implants worldwide. Vivity is the most implanted EDOF IOL globally.1* Alcon is the global leader in IOLs—every four seconds an eye is implanted with an Alcon IOL—and continues to innovate in this space to address patients’ unmet needs.5¤ “Reaching the one million milestone for Vivity, the world's leading EDOF IOL, rep...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch